Loading...
XNASMBOT
Market cap18mUSD
Dec 27, Last price  
1.11USD
1D
11.00%
1Q
28.90%
Jan 2017
-98.79%
Name

Microbot Medical Inc

Chart & Performance

D1W1MN
XNAS:MBOT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
28.56%
Rev. gr., 5y
%
Revenues
0k
141,034205,91492,85056,722231,730992,8701,426,9721,221,0001,367,9551,203,0001,012,000117,00000000000
Net income
-11m
L
-15,330,299-11,738,350-18,948,380-25,022,802-29,086,777-27,026,411-25,243,551-21,328,000-28,491,153-26,439,000-32,741,000-36,415,000-9,663,000-7,589,000-7,240,000-7,350,000-9,249,000-11,269,000104,832,000-10,740,000
CFO
-9m
L-26.11%
-11,273,908-11,870,568-16,104,120-20,856,746-22,740,421-24,682,669-24,519,913-22,058,283-19,869,344-23,322,001-27,352,431-30,679,424-786,000-4,856,000-5,310,000-6,451,000-7,252,000-9,354,000-11,549,000-8,533,000
Earnings
Mar 25, 2025

Profile

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
URL
http://www.microbotmedical.com/
IPO date
Mar 25, 1992
Employees
18
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
9,961
13,263
11,321
Unusual Expense (Income)
NOPBT
(9,961)
(13,263)
(11,321)
NOPBT Margin
Operating Taxes
(118,000)
(44)
Tax Rate
NOPAT
(9,961)
104,737
(11,277)
Net income
(10,740)
-110.24%
104,832
-1,030.27%
(11,269)
21.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,558
4,324
BB yield
-39.20%
-19.79%
Debt
Debt current
191
283
278
Long-term debt
80
641
1,082
Deferred revenue
Other long-term liabilities
Net debt
(6,114)
(7,278)
(14,132)
Cash flow
Cash from operating activities
(8,533)
(11,549)
(9,354)
CAPEX
(33)
(84)
(69)
Cash from investing activities
1,973
(3,836)
3,200
Cash from financing activities
6,558
4,324
FCF
(9,644)
104,902
(11,139)
Balance
Cash
6,385
8,202
15,492
Long term investments
Excess cash
6,385
8,202
15,492
Stockholders' equity
(79,383)
(68,681)
(55,521)
Invested Capital
84,115
76,432
70,582
ROIC
142.49%
ROCE
EV
Common stock shares outstanding
10,200
7,260
7,108
Price
1.64
-45.51%
3.01
-59.87%
7.50
8.85%
Market cap
16,728
-23.45%
21,854
-59.01%
53,311
8.71%
EV
10,614
14,576
39,179
EBITDA
(9,855)
(13,161)
(11,245)
EV/EBITDA
Interest
131,281
Interest/NOPBT